Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158554 | 0.71 | CLK1 (0.33) | CLK1DYRK1A | |
| SCHEMBL3897125 | 0.68 | CLK1 (0.32) | CLK1DYRK1A | |
| SCHEMBL455250 | 0.67 | KDM4E (0.31) | — | |
| SCHEMBL276610 | 0.65 | CYP19A1 (0.34) | CLK1DYRK1A | |
| SCHEMBL210569 | 0.65 | PRKCZ (0.33) | CLK1DYRK1A | |
| SCHEMBL3931342 | 0.62 | MAP4K4 (0.30) | CLK1DYRK1A | |
| SCHEMBL25798 | 0.62 | CLK1 (0.42) | CLK1DYRK1A | |
| SCHEMBL152013 | 0.62 | CYP19A1 (0.45) | CLK1DYRK1A | |
| SCHEMBL24185 | 0.61 | KDM4E (0.38) | CLK1DYRK1A | |
| SCHEMBL5846905 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557130-B2 | Bicyclic heteroaromatic alanines | UCB PHARMA, S.A. (BE) | 2009-07-07 | — | — | US | disclosed |
| US-20040209913-A1 | e.g., 3-[1-(3,5-Dichloroisonicotinoyl)-2,3-dihydro-1 H-indol-5-yl]-2-[(3-oxo-spiro[3.5]non-1-en-1-yl)amino]-propanoate; modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role. | UCB PHARMA S.A. (BE) | 2004-10-21 | — | — | US | disclosed |
| WO-2003011815-A1 | BICYCLIC HETEROAROMATIC ALANINES | CELLTECH R & D LIMITED (GB) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209913-A1 | e.g., 3-[1-(3,5-Dichloroisonicotinoyl)-2,3-dihydro-1 H-indol-5-yl]-2-[(3-oxo-spiro[3.5]non-1-en-1-yl)amino]-propanoate; modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role. | ICAM1, VCAM1, CCR1 | CLK1 3811/4885DYRK1A 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.